Skip to content

English

繁體中文

syneuRx-logo
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media

Blog

Q&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

  • Post author:admin
  • Post published:March 30, 2022
  • Post category:Blog

Q&A with SyneuRx Chief Scientist and CEO, Dr. Emil Tsai: What Are The Top Symptoms of The BA.2 Variant and Is It a Major Cause of Concern? Since the beginning…

Continue ReadingQ&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNA11
  • SNG12
  • SND12

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNA11
  • SNG12
  • SND12

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.okPrivacy policy